A research company in Rhode Island is looking for patients that fit the following criteria:

- Male or female, ages 12 and older.
- Diagnosis of Seborrheic Dermatitis.

Participants will receive a free evaluation, medication, and compensation.  The treatment period using a topical medication is 4 weeks.

To enroll in the study contact:

Caroline DiGiulio
Clinical Partners, LLC
1524 Atwood Avenue
Suite #330
Johnston, RI 02919
Telephone: 401-454-3800
Fax: 401-454-5959
Email: info@clinicalpartnersresearch.com

Do you have dandruff? If so you may qualify to participate in a research study to evaluate an investigational medication.

A research clinic is looking for the following people:

- Males and females, ages 12 and older.
- Been diagnosed with Seborrheic Dermatitis.

If you believe that you fit these criteria you can apply to join the study to test a new topical anti-dandruff medication.   

If selected you will receive a free evaluation, medication and compensation.   The treatment period for using the topical medication is 4 weeks.

If you are interested please contact

Caroline DiGiulio
Clinical Partners, LLC
1524 Atwood Avenue
Suite #330
Johnston, RI 02919
Telephone: 401-454-3800
Fax: 401-454-5959
Email: info@clinicalpartnersresearch.com

Neosil, Inc. is starting a new Phase 2 clinical hair loss trial in Germany and is looking for volunteers.

The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV androgenetic alopecia).

Four equally sized treatment groups (35 men each) will receive either NEOSH101 0.5%, NEOSH101 1.0%, NEOSH101 2.0% or placebo. A 12-week observation period will follow the treatment period.

The criteria for enrolling in the study are men who:

• Are aged 18 to 49 years and in general good health
• Are Norwood/Hamilton grades III - IV androgenetic alopecia, with thinning hair in the vertex area
• Are not currently using any other hair loss treatments
• Have not used minoxidil (Rogaine) for 6 months prior
• Have not used Finasteride (Propecia) for 12 months prior
• Have not used any other trial hair growth products for 6 months prior

The study will be enrolling 140 men and will start in May 2007.

If you live in Germany and are interested in participating the contact details are below.

Elisabeth Rowold, PhD  49 40 606 987 35   elisabeth.rowold@bioskin.de
Bioskin Institute for Dermatological Research and Development GmbH, Hamburg, 20095, Germany

The University of Virginia is looking for female volunteers for a hair loss study.  Researchers there have developed a computer imaging intervention in the Breast Care Center.  

To test it they are seeking women at least 18 years old who are undergoing chemotherapy with a possible side effect of temporary baldness.

Their purpose is to learn how effective two types of interventions are in reducing distress that may occur when women lose their hair due to chemotherapy.

The trial will involve the participant’s portrait being taken with a digital camera and then displayed on the computer screen. By using a touch screen, the subjects will be able to see themselves without hair and with different hair styles and colors.   They will then spend one session with a researcher in the School of Medicine discussing the experience of hair loss while viewing their image on the screen.

Participants will be asked to fill out questionnaires at 4 different time points. They will be compensated $25 each time they complete a questionnaire. They will also have the option of printing the color images to take home, if they choose.

If you are interested contact the study investigator: Dr. Elizabeth McGarvey (434) 924-5522 or by email at rel8s@virginia.edu

The purpose of this study is to measure hair growth response to a new topical hairloss treatment called NEOSH101, created by Neosil inc.

The study is a Phase 2 Multi-center, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men.

What that means is that three equally sized treatment groups of 60 balding men will receive either topical NEOSH101 2.0%, minoxidil 5%, or a placebo.  They will apply the treatments to their balding scalp twice daily for 16 weeks.

Their hair density, hair growth and hair diameter will all be measured using the TrichoScan method, which is a computerized system for measuring hair.

In addition to that physicians will assess their hair growth and also determine how well they were able to tolerate the medication.

The requirements to be eligible for the study are:

- Caucasian male
- Ages  18 - 49 Years
- Norwood/Hamilton class III-IV, with thinning hair in the vertex area
- Not currently using any other hair loss treatments
- Have not used minoxidil (Rogaine) for 6 months prior
- Have not used Finasteride (Propecia) for 12 months prior
- Have not used any other trial hair growth products for 6 months prior

The study is being conducted in Germany in February. 

If you would like to apply contact Elisabeth Rowold, PhD  tel: +49 40 606 897 34 email: elisabeth.rowold@bioskin.de

Nearly 2% of people in the United States, many of them children, suffer from alopecia areata, a skin disorder that causes hair to fall out in patches. The cause of the disease is not known, and there is presently no cure. However, researchers believe that several genetic factors may play a major role in autoimmune disease.

To gather the large amount of information needed to perform a genetic linkage analysis, M. D. Anderson is leading a study that will create a national registry of alopecia areata patients and their family members. The registry, sponsored by the National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS), is designed to collect research samples that will help determine the genetic components of alopecia areata. It is a tremendous opportunity to create a well-organized resource that will help researchers develop new treatments, diagnostic tools and prevention measures. Patients identified through the study will be first in line for clinical trials of any new therapies.

M. D. Anderson is one of five U.S. sites registering alopecia areata patients. Principal investigator for the study is Madeleine Duvic, M.D., chief of  dermatology at M. D. Anderson’s Melanoma & Skin Center, and an internationally recognized expert on skin disorders. Our goal is to enroll 2,500 people over the five-year life of the study. Registration of study participants is already under way. This site has information about alopecia areata, and everything you need to become part of the study.

For more info visit http://www.mdanderson.org/departments/alopecia/